Nicole Germino
Stock Analyst at Truist Securities
(3.64)
# 858
Out of 4,761 analysts
19
Total ratings
47.06%
Success rate
11.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $1.07 | +367.29% | 5 | Jan 23, 2025 | |
| INSM Insmed | Reiterates: Buy | $100 → $105 | $81.06 | +29.53% | 7 | Nov 1, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $21 | $2.78 | +655.40% | 1 | Sep 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $21 | $5.72 | +267.13% | 1 | Jun 28, 2024 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $12.35 | +94.33% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $10.98 | - | 2 | Sep 3, 2021 |
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $1.07
Upside: +367.29%
Insmed
Nov 1, 2024
Reiterates: Buy
Price Target: $100 → $105
Current: $81.06
Upside: +29.53%
Perspective Therapeutics
Sep 25, 2024
Initiates: Buy
Price Target: $21
Current: $2.78
Upside: +655.40%
Y-mAbs Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $21
Current: $5.72
Upside: +267.13%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $12.35
Upside: +94.33%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.98
Upside: -